뒤로
Telomir Pharmaceuticals Inc(TELO) 가격
TELO 주가 차트
TELO 수입
Telomir Pharmaceuticals Inc
$1.32
0%
$0
종가: Jan 27, 16:00:00 GMT-5
$1.31
-0.75%
$-0.01
애프터마켓: Jan 27, 20:00:00 GMT-5
최신 수익 결과: Q3 '25
보고됨: 2025-11-10
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
TELO의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Telomir Pharmaceuticals Inc TELO의 지난 분기 매출 실적은 어땠나요?
Telomir Pharmaceuticals Inc의 매출 추정치는 얼마인가요?
Telomir Pharmaceuticals Inc의 수익 품질 점수는 얼마인가요?
Telomir Pharmaceuticals Inc는 언제 수익을 보고하나요?
Telomir Pharmaceuticals Inc의 예상 수익은 얼마인가요?
Telomir Pharmaceuticals Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$1.32
시가
$1.32
일일 범위
$1.29 - $1.32
52주 범위
$1.12 - $5.4
거래량
114.2K
평균 거래량
657.1K
EPS(TTM)
-0.37
배당수익률
--
시가총액
$45.0M
TELO란 무엇인가요?
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The company is headquartered in Tampa, Florida and currently employs 0 full-time employees. The company went IPO on 2024-02-09. The firm is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. The company is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. The company is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.